Background: Sézary syndrome (SS) is a rare erythrodermic and leukemic variant of cutaneous T-cell lymphoma (CTCL) that belongs to the group of non-Hodgkin's lymphomas (NHL) resulting from malignant proliferation of skin-homing T cells. We report through a series of 5 cases, the experience of the hematology laboratory in the diagnosis of the syndrome of Sézary. Methods: This is a retrospective study of 5 cases of Sezary syndrome collected in the dermatology department of Marrakech. Results: five patients were identified with the clinicopathological criteria of SS. At the time of diagnosis, all 5 patients had erythroderma and generalized lymphadenopathy in both superficial and deep stations. The white blood cell count was elevated (>10,000 WBC/mm3) in all 5 patients with a mean value of 18,120 WBC/mm3. The blood smear showed the presence of 75% (27 G/l) of small to medium-sized cells with a high nucleocytoplasmic ratio and cerebriform nuclei typical of Sezary cells and suggests the diagnosis of SS. Conclusions: The diagnosis of SS remains a challenge in many situations, the pathophysiology and definition of SS have evolved significantly over the past decades.
Published in | American Journal of Biomedical and Life Sciences (Volume 10, Issue 2) |
DOI | 10.11648/j.ajbls.20221002.16 |
Page(s) | 42-44 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
Sezary Syndrome, Lymphoma, T-cell, Blood Smear
[1] | Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 5 août 2010; 116 (5): 767 71. |
[2] | Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 15 mai 2005; 105 (10): 3768 85. |
[3] | Imam MH, Shenoy PJ, Flowers CR, Phillips A, Lechowicz MJ. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma. avr 2013; 54 (4): 752 9. |
[4] | Klemke CD, Booken N, Weiss C, Nicolay JP, Goerdt S, Felcht M, et al. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases. Br J Dermatol. juill 2015; 173 (1): 93 105. |
[5] | Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. The Lancet. 2008; 371 (9616): 945 57. |
[6] | Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. avr 2005; 115 (4): 798 812. |
[7] | Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, et al. EORTC Classification for Primary Cutaneous Lymphomas: A Proposal From the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1 juill 1997; 90 (1): 354 71. |
[8] | Moins-Teisserenc H, Daubord M, Clave E, Douay C, Félix J, Marie-Cardine A, et al. CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells. J Invest Dermatol. janv 2015; 135 (1): 247 57. |
[9] | Moriarty B, Whittaker S. Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma. Expert Rev Hematol. avr 2015; 8 (2): 159 71. |
[10] | Querfeld C, Rosen ST, Guitart J, Kuzel TM. The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr Opin Hematol. juill 2005; 12 (4): 273 8. |
[11] | Flandrin G, Brouet JC. The Sezary cell: cytologic, cytochemical, and immunologic studies. Mayo Clin Proc. août 1974; 49 (8): 575 83. |
[12] | Vonderheid EC, Sobel EL, Nowell PC, Finan JB, Helfrich MK, Whipple DS. Diagnostic and prognostic significance of Sézary cells in peripheral blood smears from patients with cutaneous T cell lymphoma. Blood. août 1985; 66 (2): 358 66. |
[13] | Kubica AW, Pittelkow MR. Sézary Syndrome. Surgical Pathology Clinics. juin 2014; 7 (2): 191 202. |
[14] | Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 15 sept 2007; 110 (6): 1713 22. |
[15] | Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. American Journal of Hematology. 2019; 94 (9): 1027 41. |
[16] | Rappl G, Muche JM, Abken H, Sterry W, Tilgen W, Ugurel S, et al. CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sézary syndrome. J Am Acad Dermatol. mars 2001; 44 (3): 456 61. |
[17] | Vonderheid EC, Bernengo MG. The Sézary syndrome: hematologic criteria. Hematol Oncol Clin North Am. déc 2003; 17 (6): 1367 89, viii. |
APA Style
Rania Rada, Hajar Saffour, Mahjouba Baiya, Hicham Yahyaoui, Mustapha Ait Ameur, et al. (2022). Sezary Syndrome: A Clinico-biological Study of 5 Cases. American Journal of Biomedical and Life Sciences, 10(2), 42-44. https://doi.org/10.11648/j.ajbls.20221002.16
ACS Style
Rania Rada; Hajar Saffour; Mahjouba Baiya; Hicham Yahyaoui; Mustapha Ait Ameur, et al. Sezary Syndrome: A Clinico-biological Study of 5 Cases. Am. J. Biomed. Life Sci. 2022, 10(2), 42-44. doi: 10.11648/j.ajbls.20221002.16
AMA Style
Rania Rada, Hajar Saffour, Mahjouba Baiya, Hicham Yahyaoui, Mustapha Ait Ameur, et al. Sezary Syndrome: A Clinico-biological Study of 5 Cases. Am J Biomed Life Sci. 2022;10(2):42-44. doi: 10.11648/j.ajbls.20221002.16
@article{10.11648/j.ajbls.20221002.16, author = {Rania Rada and Hajar Saffour and Mahjouba Baiya and Hicham Yahyaoui and Mustapha Ait Ameur and Mohamed Chakour}, title = {Sezary Syndrome: A Clinico-biological Study of 5 Cases}, journal = {American Journal of Biomedical and Life Sciences}, volume = {10}, number = {2}, pages = {42-44}, doi = {10.11648/j.ajbls.20221002.16}, url = {https://doi.org/10.11648/j.ajbls.20221002.16}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20221002.16}, abstract = {Background: Sézary syndrome (SS) is a rare erythrodermic and leukemic variant of cutaneous T-cell lymphoma (CTCL) that belongs to the group of non-Hodgkin's lymphomas (NHL) resulting from malignant proliferation of skin-homing T cells. We report through a series of 5 cases, the experience of the hematology laboratory in the diagnosis of the syndrome of Sézary. Methods: This is a retrospective study of 5 cases of Sezary syndrome collected in the dermatology department of Marrakech. Results: five patients were identified with the clinicopathological criteria of SS. At the time of diagnosis, all 5 patients had erythroderma and generalized lymphadenopathy in both superficial and deep stations. The white blood cell count was elevated (>10,000 WBC/mm3) in all 5 patients with a mean value of 18,120 WBC/mm3. The blood smear showed the presence of 75% (27 G/l) of small to medium-sized cells with a high nucleocytoplasmic ratio and cerebriform nuclei typical of Sezary cells and suggests the diagnosis of SS. Conclusions: The diagnosis of SS remains a challenge in many situations, the pathophysiology and definition of SS have evolved significantly over the past decades.}, year = {2022} }
TY - JOUR T1 - Sezary Syndrome: A Clinico-biological Study of 5 Cases AU - Rania Rada AU - Hajar Saffour AU - Mahjouba Baiya AU - Hicham Yahyaoui AU - Mustapha Ait Ameur AU - Mohamed Chakour Y1 - 2022/04/20 PY - 2022 N1 - https://doi.org/10.11648/j.ajbls.20221002.16 DO - 10.11648/j.ajbls.20221002.16 T2 - American Journal of Biomedical and Life Sciences JF - American Journal of Biomedical and Life Sciences JO - American Journal of Biomedical and Life Sciences SP - 42 EP - 44 PB - Science Publishing Group SN - 2330-880X UR - https://doi.org/10.11648/j.ajbls.20221002.16 AB - Background: Sézary syndrome (SS) is a rare erythrodermic and leukemic variant of cutaneous T-cell lymphoma (CTCL) that belongs to the group of non-Hodgkin's lymphomas (NHL) resulting from malignant proliferation of skin-homing T cells. We report through a series of 5 cases, the experience of the hematology laboratory in the diagnosis of the syndrome of Sézary. Methods: This is a retrospective study of 5 cases of Sezary syndrome collected in the dermatology department of Marrakech. Results: five patients were identified with the clinicopathological criteria of SS. At the time of diagnosis, all 5 patients had erythroderma and generalized lymphadenopathy in both superficial and deep stations. The white blood cell count was elevated (>10,000 WBC/mm3) in all 5 patients with a mean value of 18,120 WBC/mm3. The blood smear showed the presence of 75% (27 G/l) of small to medium-sized cells with a high nucleocytoplasmic ratio and cerebriform nuclei typical of Sezary cells and suggests the diagnosis of SS. Conclusions: The diagnosis of SS remains a challenge in many situations, the pathophysiology and definition of SS have evolved significantly over the past decades. VL - 10 IS - 2 ER -